Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Ocrevus (ocrelizumab)
pCPA File Number:
21033
Negotiation Status:
Concluded with an LOI
Indication(s):
Primary Progressive Multiple Sclerosis
Sponsor/Manufacturer:
Hoffmann-La Roche
CADTH Project Number:
SR0542-000
pCPA Engagement Letter Issued:
2018-07-19
Negotiation Process Concluded:
2019-02-13